Merck completes a clinical trial Odyssey, finally bagging an FDA OK for C diff antibody
Merck had to endure delays and some scolding by experts along the way, but the pharma giant has picked up the FDA’s approval to start marketing bezlotoxumab to prevent the recurrence of Clostridium difficile infections. The drug will be sold as Zinplava, with a launch planned for early 2017.
Picked up from Medarex just months before the Bristol-Myers’ buyout, Merck $MRK believes that the IgG1/kappa antibody can help prevent tens of thousands of new cases of C. diff each year among high-risk patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.